Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / MGNX - MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects


MGNX - MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects

2024-02-19 22:23:22 ET

Summary

  • MacroGenics' stock has increased by 230% since September due to favorable macroeconomics and interest in antibody-drug conjugates.
  • The company is testing vobramitamab duocarmazine for the treatment of metastatic castration-resistant prostate cancer.
  • MacroGenics has a strong financial position, promising pipeline, and positive market sentiment, making it a compelling "Buy" opportunity.

Introduction

MacroGenics ' ( MGNX ) stock is up 230% since my "Buy" recommendation in September....

For further details see:

MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects
Stock Information

Company Name: MacroGenics Inc.
Stock Symbol: MGNX
Market: NASDAQ
Website: macrogenics.com

Menu

MGNX MGNX Quote MGNX Short MGNX News MGNX Articles MGNX Message Board
Get MGNX Alerts

News, Short Squeeze, Breakout and More Instantly...